ScottsMiracle-Gro Announces Strong Fourth Quarter Results; U.S. Consumer and Hawthorne Segments Exceed Expectations
U.S. Consumer segment sales increase 8% for full year, up 4% in Q4.
Read More
Category: Financial
Zynerba Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational Highlights
The third quarter of 2019 was a remarkable period of progress and execution for Zynerba.
Read More
Cara Therapeutics Reports Third Quarter 2019 Financial Results
The company completed several key clinical, financing and licensing objectives that position the Company well during the quarter.
Read More
CV Sciences, Inc. Reports Third Quarter 2019 Financial Results
The company Increased Retail Distribution by Over 800 Stores.
Read More
GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the Third Quarter Ended September 30, 2019
Epidiolex U.S. year to date net sales of $188.0 million, including Q3 net sales of $86.1 million.
Read MoreGET LISTED
